• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alterity Therapeutics Limited - American Depositary Shares (NQ:ATHE)

4.030 -0.640 (-13.70%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 76,895
Open 4.450
Bid (Size) 4.010 (200)
Ask (Size) 4.960 (100)
Prev. Close 4.670
Today's Range 3.840 - 4.480
52wk Range 2.660 - 7.000
Shares Outstanding 2,084,016,678
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
May 11, 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
May 07, 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire

Performance

YTD
+27.5%
+27.5%
1 Month
+8.0%
+8.0%
3 Month
+15.6%
+15.6%
6 Month
+4.9%
+4.9%
1 Year
+6.3%
+6.3%

More News

Read More
News headline image
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
April 30, 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
April 27, 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
April 22, 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
April 17, 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
April 16, 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
April 15, 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
March 30, 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
March 09, 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
March 04, 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
March 02, 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
January 30, 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
January 21, 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference
November 12, 2025
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System
November 10, 2025
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
October 31, 2025
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
October 14, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
October 09, 2025
Via Benzinga
News headline image
Thursday's after hours session: top gainers and losers ↗
October 09, 2025
Via Chartmill
News headline image
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
October 09, 2025
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
October 02, 2025
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
September 15, 2025
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Raises A$20.0 million in Strategic Placement
September 08, 2025
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Present at the Biotech Showcase
September 02, 2025
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire

Frequently Asked Questions

Is Alterity Therapeutics Limited - American Depositary Shares publicly traded?
Yes, Alterity Therapeutics Limited - American Depositary Shares is publicly traded.
What exchange does Alterity Therapeutics Limited - American Depositary Shares trade on?
Alterity Therapeutics Limited - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Alterity Therapeutics Limited - American Depositary Shares?
The ticker symbol for Alterity Therapeutics Limited - American Depositary Shares is ATHE on the Nasdaq Stock Market
What is the current price of Alterity Therapeutics Limited - American Depositary Shares?
The current price of Alterity Therapeutics Limited - American Depositary Shares is 4.030
When was Alterity Therapeutics Limited - American Depositary Shares last traded?
The last trade of Alterity Therapeutics Limited - American Depositary Shares was at 05/15/26 03:59 PM ET
What is the market capitalization of Alterity Therapeutics Limited - American Depositary Shares?
The market capitalization of Alterity Therapeutics Limited - American Depositary Shares is 8.40B
How many shares of Alterity Therapeutics Limited - American Depositary Shares are outstanding?
Alterity Therapeutics Limited - American Depositary Shares has 8B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap